Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06606340
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
None
First Post:
2024-08-08
Brief Title:
A Long-term Observational Study Evaluating Eteplirsen Golodirsen or Casimersen in Routine Clinical Practice
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Long-term Observational Study Evaluating Sarepta Therapeutics Incs Exon-Skipping Therapies in Patients With Duchenne Muscular Dystrophy Under Conditions of Routine Clinical Practice
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EVOLVE
Brief Summary:
This is a phase 4 multicenter prospective observational study designed to collect both medical history data and prospective data on Duchenne Muscular Dystrophy DMD treatment outcomes in participants receiving eteplirsen golodirsen and casimersen in routine clinical practice Participants in this study will have been prescribed eteplirsen golodirsen or casimersen commercially prior to entry into the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None